查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016958

心室輔助裝置市場：2026-2032年全球市場預測（依裝置類型、類別、流量等級、適應症及最終用戶分類）

Ventricular Assist Device Market by Device Type, Category, Flow Class, Indication, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，心室輔助裝置市場價值將達到 15 億美元，到 2026 年將成長至 16.3 億美元，到 2032 年將達到 27.2 億美元，複合年成長率為 8.78%。

主要市場統計數據
基準年 2025 15億美元
預計年份：2026年 16.3億美元
預測年份 2032 27.2億美元
複合年成長率 (%) 8.78%

針對心室輔助裝置環境的綜合框架，重點在於臨床發展、技術整合以及醫療保健系統的需求。

過去十年間，心室輔助裝置已從最初的小眾救命療法發展成為進行進行性心臟衰竭治療路徑中不可或缺的選擇，這主要得益於其耐用性、生物相容性和植入技術的進步。現代裝置設計優先考慮降低血栓形成風險、小型化和提高能源效率，從而擴大了其在老年患者和併發症疾病患者中的應用範圍。同時，先進的外科手術方法和經皮支持策略降低了手術全期風險，使得心室輔助裝置在三級醫療機構和專科醫療機構中得到更廣泛的應用。

臨床、工程和商業領域的整合變革如何推動機械循環支援領域的新路徑和基於價值的方法。

多項因素的融合正在重塑心室輔助裝置的研發、評估和應用。首先，包括軸流式和離心式平台在內的連續流設計工程技術的進步，提高了血流動力學效率和耐久性，從而影響手術適應症的選擇和長期管理。其次，數位遙測和遠端監測功能的整合，使得對裝置性能和患者狀態進行主動管理成為可能，縮短了門診患者和植入團隊之間的反饋週期。

2025 年美國關稅變化將如何促使整個設備生態系統的供應鏈在地化、採購流程重組和商業策略調整？

2025年實施的關稅調整增加了心室輔助裝置整個供應鏈的複雜性，影響到組件、完整系統以及相關一次性用品。這些政策變化促使醫院採購團隊和醫療設備製造商更嚴格地審查採購流程，並重新評估籌資策略、供應商多元化和庫存管理。為此，一些製造商正在加快關鍵組件的在地化生產，並利用契約製造生產來降低貿易相關價格波動帶來的風險。

本研究旨在闡明流程架構、設備類型、臨床適應症、產品設計和護理環境如何相互交織，形成差異化的臨床和商業性路徑。

連續流系統和脈動平台在血流架構上的差異持續影響臨床實務。連續流裝置（尤其是軸流和離心式裝置）因其可靠性和小型化而備受青睞，而脈動技術則佔據著特定的細分市場，因為生理性脈動在臨床上更受青睞。將裝置類型分為左心室、右心室和雙心室系統，凸顯了治療目標如何驅動技術設計。左心室輔助仍然是慢性病治療中最常用的模式，而右心室和雙心室解決方案在急性心臟衰竭和複雜的圍手術全期病例中發揮著至關重要的作用。

法規結構、支付方趨勢以及臨床引入方面的區域差異，塑造了世界各地不同的商業化和證據生成策略。

美洲地區擁有完善的三級醫療網路、高度集中的專業植入中心，以及強調可靠臨床證據和上市後監測的監管流程。這些條件有利於先進植入技術和複雜護理方案的推廣應用。相較之下，歐洲、中東和非洲（EMEA）地區的醫療環境高度異質化，報銷機制、國家衛生部門流程和醫院採購模式差異顯著，因此需要靈活的商業化策略和針對特定區域的臨床合作。同時，亞太地區某些市場的醫療基礎設施正在快速發展，而其他市場則擁有高度先進、卓越的醫療中心，因此該地區的兩大重點在於：成本效益高的解決方案和尖端創新技術的應用。

競爭動態和夥伴關係策略強調平台創新、服務整合以及在整個設備生態系統中基於證據的差異化。

行業相關人員採取了多種策略來實現產品差異化。一些公司優先考慮對醫療設備進行漸進式改進，以提高生物相容性和電池效率；而另一些公司則專注於平台主導舉措，整合遠端監控和預測分析。醫療設備開發商與學術機構之間的策略合作正在加速轉化研究和臨床檢驗，並加快迭代改進週期。此外，服務網路的垂直整合和內部技術支援團隊的擴充，正成為企業與醫院建立長期合作關係並維持植入式醫療設備高運轉率的關鍵差異化因素。

製造商和供應商在醫療設備治療領域加強供應韌性、證據產生和價值主導經營模式的具體策略重點。

首先，我們將優先投資於上市後資料收集和遠端監測基礎設施，以驗證設備在真實臨床環境中的性能，並促進其早期臨床應用。將循證研究與支付方的要求和臨床醫生的優先事項相結合，將簡化報銷談判流程，並促進更廣泛的應用。其次，我們將實現關鍵零件供應商多元化，並盡可能探索本地製造夥伴關係，以降低貿易中斷和前置作業時間波動帶來的風險，從而增強供應鏈的韌性。第三，我們將開發包含醫療設備硬體、保固服務和可預測服務合約的捆綁式商業方案，以簡化採購流程，並降低醫院系統的營運風險。

採用嚴謹的混合方法研究方法，結合一手臨床訪談、二手證據和相關人員檢驗，以獲得可靠的研究結果。

本研究途徑融合了定性和定量方法，旨在全面了解臨床實踐、技術趨勢和商業性動態。主要資料收集包括對臨床醫生、臨床工程師、採購經理和監管專家進行結構化訪談，以獲取關於設備性能、服務期望和推廣障礙的實際觀點。次要文獻整合則利用同行評審的臨床研究、指南、監管公告和技術白皮書，為主要研究結果提供背景資訊並檢驗臨床結論。

簡明扼要地整合了技術進步、不斷發展的臨床實踐和策略挑戰，以實現機械循環支援的永續發展。

總而言之，心室輔助裝置（VAD）領域正處於一個轉折點，技術進步、不斷演變的臨床適應症和不斷變化的商業性環境相互交織，既帶來了新的機遇，也帶來了新的挑戰。設備在血流技術、小型化和數位化整合方面的改進，使得更多患者能夠受益，並能實現更精細的治療路徑。同時，與定價相關的供應鏈壓力以及監管和報銷體系的區域差異，要求企業制定靈活的商業性和營運策略。因此，那些能夠將卓越的技術、強大的實證醫學能力、穩健的供應鏈網路以及完善的臨床醫生和患者支持計劃相結合的機構，才能最終取得成功。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：心室輔助裝置市場：依裝置類型分類

  • 雙心室型
  • 左邊
  • 正確的

第9章：心室輔助裝置市場：依類別分類

  • 種植類型
  • 體外型

第10章 依流量類型分類的心室輔助裝置市場

  • 連續流
    • 軸流式
    • 圓神流
  • 脈衝流

第11章 心室輔助裝置市場：依適應症分類

  • 彌合復甦差距
  • 彌合移植差距
  • 最終治療

第12章 心室輔助裝置市場：依最終使用者分類

  • 門診手術中心
  • 醫院

第13章 心室輔助裝置市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 心室輔助裝置市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 心室輔助裝置市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國心室輔助裝置市場

第17章 中國心室輔助裝置市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Abiomed
  • Berlin Heart GmbH
  • BiVACOR Inc.
  • Calon Cardio-Technology Ltd.
  • CARMAT SA
  • CH Biomedical Inc.
  • CorWave SAS
  • Evaheart, Inc.
  • Jarvik Heart, Inc.
  • LivaNova PLC
  • Medtronic plc
  • ReliantHeart Inc.
  • SynCardia Systems, LLC
  • Terumo Corporation
Product Code: MRR-034B5003038B

The Ventricular Assist Device Market was valued at USD 1.50 billion in 2025 and is projected to grow to USD 1.63 billion in 2026, with a CAGR of 8.78%, reaching USD 2.72 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.50 billion
Estimated Year [2026] USD 1.63 billion
Forecast Year [2032] USD 2.72 billion
CAGR (%) 8.78%

A comprehensive framing of the ventricular assist device environment highlighting clinical evolution, technology convergence, and health-system imperatives

Over the past decade, ventricular assist devices have transitioned from niche salvage therapies to integral options within advanced heart failure care pathways, driven by improvements in durability, biocompatibility, and implantation techniques. Contemporary device architectures emphasize reduced thrombogenicity, smaller form factors, and energy efficiency, which together have expanded candidacy among older and more comorbid patients. Simultaneously, refined surgical approaches and percutaneous-adjunct strategies have lowered perioperative risk, thereby enabling wider institutional adoption across tertiary and specialized centers.

Moreover, shifting clinical paradigms have blurred traditional boundaries between temporary and long-term mechanical circulatory support, prompting clinicians to consider device therapy earlier in the disease course for select patient cohorts. Payers and health systems are increasingly focused on value-based outcomes and readmission reduction, which elevates the importance of longitudinal device performance and comprehensive peri-implant care programs. As a result, manufacturers, clinicians, and hospitals are coalescing around evidence-generation and real-world data initiatives to quantify quality-of-life improvements and long-term survival benefits.

In parallel, regulatory frameworks continue to evolve to balance timely patient access with robust post-market surveillance, encouraging iterative device enhancements while maintaining patient safety. Taken together, these dynamics have created a complex but fertile environment for innovation, partnership, and strategic differentiation across the ecosystem supporting ventricular assist device therapy.

How convergent clinical, engineering, and commercial transformations are driving new adoption pathways and value-based approaches in mechanical circulatory support

Several convergent shifts are redefining how ventricular assist devices are developed, evaluated, and deployed. First, engineering advances in continuous flow designs, including axial and centrifugal platforms, have enhanced hemodynamic efficiency and durability, which in turn influence surgical selection and long-term management. Second, integration of digital telemetry and remote monitoring capabilities is enabling proactive management of device performance and patient status, thus shortening feedback loops between outpatient clinicians and implant teams.

Concurrently, clinical evidence is expanding indications beyond classic bridge-to-transplant scenarios toward bridge-to-recovery and destination therapy for select populations, prompting multidisciplinary teams to reassess candidacy criteria. The rise of patient-centered outcomes has shifted evaluation metrics to include functional status and quality of life, not solely survival, which affects reimbursement conversations and clinical adoption. Furthermore, manufacturing and supply chain strategies are evolving as companies pursue vertical integration, production scalability, and regulatory harmonization across jurisdictions to reduce time to market for iterative device updates.

Finally, strategic collaborations among device manufacturers, academic centers, and health systems are accelerating translational research and real-world evidence generation. These partnerships are fostering adaptive clinical trial designs and registries that better capture long-term device performance and complications, thereby informing iterative improvements in patient selection, perioperative protocols, and post-implant care.

Assessing how 2025 United States tariff changes are prompting supply chain localization, procurement realignment, and commercial strategy adjustments across the device ecosystem

Tariff adjustments implemented in 2025 have introduced complexity across the ventricular assist device supply chain, affecting components, finished systems, and ancillary disposables. These policy changes have increased procurement scrutiny among hospital purchasing teams and device manufacturers, prompting reassessments of sourcing strategies, supplier diversification, and inventory management. In response, some manufacturers have accelerated localization of critical component production and engaged contract manufacturers to mitigate exposure to trade-related price volatility.

Healthcare providers have reacted by enhancing procurement governance and exploring longer-term supply agreements to provide price stability and continuity of care. At the same time, smaller suppliers and niche component vendors have experienced differential impacts, leading to potential consolidation as organizations seek scale to absorb tariff-related cost pressures. Importantly, clinical teams are monitoring any indirect effects on device availability and service parts, because even modest disruptions can influence scheduled implant programs and post-implant support.

Policy uncertainty has also elevated the role of total cost of care analyses in procurement decisions, with hospital systems demanding greater transparency around landed costs, warranty terms, and service network reliability. As a result, manufacturers that proactively adapt their commercial models to offer bundled service agreements, improved lead-time assurances, and localized support are positioned to maintain competitive advantage under the revised tariff environment.

Decoding how flow architecture, device type, clinical indication, product design, and care setting intersect to create differentiated clinical and commercial pathways

Flow architecture distinctions between continuous flow systems and pulsatile platforms continue to shape clinical practice, with continuous flow devices-particularly axial and centrifugal configurations-favored for their reliability and smaller profiles, whereas pulsatile technologies retain a defined niche where physiologic pulsatility is clinically prioritized. Device type segmentation into left, right, and biventricular systems underscores how therapeutic intent drives technological design; left ventricular support remains the most commonly deployed modality for chronic support, while right and biventricular solutions play critical roles in acute decompensation and complex perioperative cases.

Indication-based differentiation across bridge-to-recovery, bridge-to-transplant, and destination therapy informs not only clinical decision-making but also programmatic design within health systems, as each indication demands distinct pre-implant evaluation, follow-up care pathways, and psychosocial support models. Product-level choices between external and implantable systems further interact with patient lifestyle considerations, infection risk management, and long-term device maintenance strategies. Finally, end-user segmentation that includes ambulatory surgical centers alongside hospitals highlights evolving care-delivery models, with ambulatory settings increasingly managing select perioperative workflows while hospitals retain responsibility for complex implants and long-term management.

Together, these segmentation axes intersect to create nuanced adoption patterns and service needs, suggesting that manufacturers and providers who align product development, clinical support, and training programs to these differentiated requirements will be better positioned to address clinician preferences and patient expectations.

Regional distinctions in regulatory frameworks, payer dynamics, and clinical adoption that shape commercialization and evidence-generation strategies across global territories

The Americas region features advanced tertiary care networks, a high concentration of specialized implant centers, and regulatory pathways that emphasize robust clinical evidence and post-market surveillance; these conditions support the adoption of advanced implantable technologies and complex care programs. In contrast, Europe, Middle East & Africa presents a heterogeneous landscape where reimbursement mechanisms, national health authority processes, and hospital procurement models vary significantly, driving the need for flexible commercialization strategies and region-specific clinical engagement. Meanwhile, Asia-Pacific encompasses rapidly developing health infrastructure in certain markets alongside highly advanced centers of excellence in others, creating a dual focus on cost-effective solutions and cutting-edge innovation adoption.

Across these regions, local clinical practice patterns, surgeon experience, and the density of specialized heart failure programs influence how quickly new device architectures are integrated into treatment algorithms. Furthermore, regulatory harmonization efforts and regional initiatives to strengthen post-market data collection are beginning to reduce barriers to multi-jurisdictional evidence generation, although implementation timelines remain uneven. As a result, companies pursuing global expansion must tailor clinical education, service networks, and reimbursement strategies to accommodate diverse payer expectations and healthcare delivery models while leveraging regional centers of excellence to accelerate clinician adoption and build robust real-world evidence.

Competitive dynamics and partnership strategies that emphasize platform innovation, service integration, and evidence-led differentiation across the device ecosystem

Industry participants have pursued divergent strategies to differentiate offerings: some prioritize incremental device refinements to improve hemocompatibility and battery efficiency, while others emphasize platform initiatives that integrate remote monitoring and predictive analytics. Strategic partnerships between device developers and academic institutions have accelerated translational research and clinical validation, enabling faster cycles of iterative improvement. In addition, vertical integration of service networks and the expansion of in-house technical support teams have emerged as critical differentiators for companies seeking to secure long-term hospital relationships and ensure high uptime for implanted devices.

Mergers and acquisitions remain a pathway for acquiring complementary technologies, bolstering service capabilities, and expanding geographic reach, particularly where companies seek to plug gaps in product lines or augment post-market surveillance infrastructure. At the same time, newer entrants and specialized component suppliers are challenging incumbents by offering niche innovations in areas such as driveline infection mitigation, sensor integration, and hemodynamic optimization algorithms. Collectively, these competitive dynamics prioritize not only device performance but also the quality of clinical training, clarity of warranty and service commitments, and the depth of evidence supporting long-term patient outcomes.

Actionable strategic priorities for manufacturers and providers to reinforce supply resilience, evidence generation, and value-driven commercial models in device therapy

First, prioritize investment in post-market data collection and remote monitoring infrastructure to demonstrate real-world device performance and drive earlier clinical acceptance. Aligning evidence-generation efforts with payer requirements and clinician priorities will facilitate reimbursement discussions and support broader adoption. Second, strengthen supply chain resilience by diversifying suppliers of critical components and by exploring localized manufacturing partnerships where feasible to reduce exposure to trade-related disruption and lead-time variability. Third, develop bundled commercial offerings that combine device hardware, warranty coverage, and predictable service agreements to simplify procurement and reduce operational risk for hospital systems.

Moreover, expand clinician education programs that incorporate simulation, proctorship, and multidisciplinary care-team training to minimize perioperative complications and optimize patient selection. Leverage regional centers of excellence to accelerate peer-to-peer knowledge transfer and to generate high-quality real-world evidence. Finally, adopt a patient-centered product development mindset that emphasizes quality of life, ease of use, and long-term care coordination, because these factors increasingly drive device preference among clinicians and patients alike. By implementing these recommendations in concert, leaders can strengthen competitive positioning while improving clinical outcomes and operational reliability.

A rigorous mixed-methods research approach integrating primary clinical interviews, secondary evidence synthesis, and stakeholder validation for reliable insights

The research approach integrates qualitative and quantitative methods to produce a comprehensive view of clinical practice, technology trends, and commercial dynamics. Primary data collection involves structured interviews with clinicians, clinical engineers, procurement leaders, and regulatory specialists to capture frontline perspectives on device performance, service expectations, and adoption barriers. Secondary literature synthesis draws on peer-reviewed clinical studies, guideline statements, regulatory communications, and technical white papers to contextualize primary findings and to verify clinical assertions.

In addition, structured stakeholder validation sessions were used to reconcile divergent viewpoints, test hypotheses emerging from the analysis, and refine recommendations. Where appropriate, device technical specifications, bench-test reports, and post-market surveillance summaries were cross-referenced to corroborate claims about device architecture and clinical application. Throughout, methodological rigor was maintained by applying transparent inclusion criteria for sources, documenting interview protocols, and employing iterative triangulation to enhance reliability. This mixed-methods design ensures that the insights are both clinically grounded and operationally relevant for decision-makers.

A concise synthesis linking technological advancement, clinical practice evolution, and strategic imperatives for sustainable progress in mechanical circulatory support

In synthesis, the ventricular assist device field is at an inflection point where engineering advances, evolving clinical indications, and shifting commercial realities converge to create new opportunities and challenges. Device improvements in flow technology, miniaturization, and digital integration are enabling broader patient access and more refined care pathways, while tariff-related supply-chain pressures and regional variability in regulation and reimbursement require adaptive commercial and operational strategies. Consequently, successful organizations will be those that combine technical excellence with robust evidence-generation, resilient supply networks, and comprehensive clinician and patient support programs.

Looking ahead, coordinated efforts among manufacturers, clinical leaders, and health systems to prioritize real-world data collection, streamline procurement models, and enhance training will be essential to translate technological promise into sustained clinical benefit. By focusing on these integrated priorities, stakeholders can improve patient outcomes, reduce system-level risks, and position device therapy as a durable, patient-centered option within advanced heart failure care paradigms.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ventricular Assist Device Market, by Device Type

  • 8.1. Biventricular
  • 8.2. Left
  • 8.3. Right

9. Ventricular Assist Device Market, by Category

  • 9.1. Implantable
  • 9.2. External

10. Ventricular Assist Device Market, by Flow Class

  • 10.1. Continuous Flow
    • 10.1.1. Axial Flow
    • 10.1.2. Centrifugal Flow
  • 10.2. Pulsatile Flow

11. Ventricular Assist Device Market, by Indication

  • 11.1. Bridge To Recovery
  • 11.2. Bridge To Transplant
  • 11.3. Destination Therapy

12. Ventricular Assist Device Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals

13. Ventricular Assist Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Ventricular Assist Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Ventricular Assist Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Ventricular Assist Device Market

17. China Ventricular Assist Device Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Abiomed
  • 18.7. Berlin Heart GmbH
  • 18.8. BiVACOR Inc.
  • 18.9. Calon Cardio-Technology Ltd.
  • 18.10. CARMAT SA
  • 18.11. CH Biomedical Inc.
  • 18.12. CorWave SAS
  • 18.13. Evaheart, Inc.
  • 18.14. Jarvik Heart, Inc.
  • 18.15. LivaNova PLC
  • 18.16. Medtronic plc
  • 18.17. ReliantHeart Inc.
  • 18.18. SynCardia Systems, LLC
  • 18.19. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VENTRICULAR ASSIST DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BIVENTRICULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BIVENTRICULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BIVENTRICULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY LEFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY LEFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY LEFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY RIGHT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY RIGHT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY RIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY IMPLANTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY IMPLANTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY IMPLANTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTERNAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTERNAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTERNAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AXIAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AXIAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AXIAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CENTRIFUGAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CENTRIFUGAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CENTRIFUGAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PULSATILE FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PULSATILE FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PULSATILE FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 115. GCC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. GCC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 120. GCC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. GCC VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 136. G7 VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. G7 VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 141. G7 VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. G7 VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 143. NATO VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 146. NATO VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. NATO VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 148. NATO VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. NATO VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)